CHALLENGES IN THE MANAGEMENT AND DIAGNOSIS OF MENOPAUSAL GENITOURINARY SYNDROME
Abstract
Menopausal Genitourinary Syndrome (MGUS) is a chronic, progressive condition resulting from declining estrogen levels that affects the genital tract and the lower urinary tract, and can cause vaginal dryness, dyspareunia, urinary symptoms, and a significant decline in women’s quality of life. Despite its high prevalence in postmenopausal women, MGS remains underdiagnosed and undertreated due to underreporting of symptoms, patient embarrassment, and the predominance of diagnostic tools based on subjective assessment. The objective of this study was to analyze the main challenges related to the diagnosis and management of GMS, addressing available treatment options, the role of new technologies, and specific considerations in the management of breast cancer survivors. This is a narrative review of the literature conducted in the PubMed database, including full-text publications in Portuguese and English from the past five years. Diagnosis is based on the medical history and gynecological examination and may be supplemented by symptom scales, assessment of vaginal pH, and the epithelial maturation index. Management includes nonhormonal therapies (lubricants and moisturizers), low-dose vaginal estrogen therapy, prasterone, and ospemifene, whereas energy-based therapies (vaginal laser) require further clarification regarding their long-term efficacy and safety. In breast cancer survivors, the approach must be strictly individualized, taking into account any adjuvant endocrine therapy currently in use. It is concluded that active investigation of symptoms and personalized care are essential to mitigate underdiagnosis and optimize the quality of life for this population.